内分泌蛋白-A受体阻塞防止左心室缩和功能障碍在盐敏感的实验性高血压
Lars Rothermund1, Roland Vetter, Maike Dieterich
1Institut für Klinische Pharmakologie, Benjamin Franklin Hospital, Freie Universität Berlin, Berlin, Germany.
Circulation
|October 31, 2002
概括
达鲁森坦是一种内甲素A受体对手,有效地预防了对盐敏感高血压的左心室缩和功能障碍. 这项研究突出了除了降低血压之外,它在治疗心脏并发症方面的潜力.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 高血压研究 高血压研究
背景情况:
- 盐敏感性高血压是左心室 (LV) 功能障碍的主要驱动因素.
- 了解预防高血压心脏损伤的机制至关重要.
研究的目的:
- 为了研究达鲁森坦 (darusentan) - - 一种选择性内甲素-A (ETA) 受体对抗剂 - - 对高血压,LV缩 (LVH) 和功能障碍的影响.
- 为了评估达鲁森坦在对盐敏感高血压的遗传大鼠模型中的疗效.
主要方法:
- 使用的Sabra (SBH/y) 敏感盐和SBN/y耐盐的老鼠.
- 使用脱氧皮质乙酸盐 (DOCA) 和盐诱导的高血压,有或没有达鲁森坦治疗.
- 评估了静缩血压,心肺重量,心脏功能标志物 (心肺末腹压, -dP/dtmax),心脏基因表达 (ANF) 和蛋白质水平 (SR Ca2+-ATPase,斯福兰本).
主要成果:
- 仅在对盐敏感的SBH/y大鼠中,DOCA盐治疗显著增加了血压,LV体重,并诱导了LV功能障碍和心脏基因/蛋白质改变.
- 达鲁森坦治疗降低了50%的缩血压,并完全预防了LVH和LV功能障碍.
- 达鲁森坦使质网膜 (SR) Ca2+再吸收和SR Ca2+-ATPase与斯福兰班的比率正常化,但没有影响间歇性纤维化.
结论:
- 达鲁森坦的ETA受体阻塞在预防盐敏感高血压中的LVH和LV功能障碍方面表现出显著的有效性.
- 达鲁森坦对心脏的保护作用超出了降血压的能力.
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...


